DNA icon

TNXB-Related Disorders via the TNXB Gene

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
TNXB 81479 81479,81479 $1190
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
7533TNXB81479 81479,81479 $1190 Order Options and Pricing

Pricing Comments

Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.

EMAIL CONTACTS

Genetic Counselors

Geneticist

  • Wuyan Chen, PhD

Clinical Features and Genetics

Clinical Features

Ehlers-Danlos syndrome (EDS), due to complete tenascin-X deficiency, is an autosomal recessive disorder of connective tissues characterized by hyperextensible skin, hypermobile joints, and tissue fragility (Burch et al. 1997. PubMed ID: 9288108; Schalkwijk et al. 2001. PubMed ID: 11642233; Lindor et al. 2005. PubMed ID: 15793839; Bristow et al. 2005. PubMed ID: 16278880; Demirdas et al. 2017. PubMed ID: 27582382). The major clinical features of this condition resemble the classic type of Ehlers-Danlos syndrome, except for lack of poor wound healing and atrophic scarring. Large joint dislocations are the most frequent debilitating finding, and easy bruising is a prominent feature. Some documented patients were also affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency because these patients were homozygous for a contiguous 30kb deletion disrupting both the CYP21A2 and TNXB genes. Patients also have features that are not typically found in Ehlers-Danlos syndrome, such as spina bifida occulta, mitral valve prolapse, gastrointestinal bleeding, severe diverticular intestinal disease with ruptured diverticula, pancolonic diverticulitis, rectal prolapse, premature arteriosclerosis, stroke, and obstructive airway disease (Schalkwijk et al. 2001. PubMed ID: 11642233; Lindor et al. 2005. PubMed ID: 15793839). These patients are rare in the literature, and the exact incidence is unknown. Symptoms could be apparent during childhood while age of onset varies into adulthood.

Heterozygous TNXB deficiency has also been associated with hypermobility type of Ehlers-Danlos syndrome, suggesting an autosomal dominant inheritance. It is characterized by joint hypermobility often in association with joint subluxations and chronic musculoskeletal pain (Levy 2013. PubMed ID: 20301456; Zweers et al. 2003. PubMed ID: 12865992; Merke et al. 2013. PubMed ID: 23284009). Compared with other types of Ehlers-Danlos syndrome, the hypermobility type is more common, but much less severe. Its clinical presentations are extremely variable, and its molecular etiology is largely unknown. Tenascin-X haploinsufficiency has been reported to explain the causes in some patients (Levy 2013. PubMed ID: 20301456; Zweers et al. 2003. PubMed ID: 12865992; Zweers et al. 2005. PubMed ID: 15733269). Of note, the contiguous 30kb deletion disrupting both CYP21A2 and TNXB genes is common in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, and tenascin-X haploinsufficiency has been associated with Ehlers-Danlos syndrome features in those patients who are heterozygous for this contiguous deletion (Chen et al. 2009. PubMed ID: 19921645; Merke et al. 2013. PubMed ID: 23284009; Morissette et al. 2015. PubMed ID: 26075496; Chen et al. 2016. PubMed ID: 27297501). In addition, cardiac abnormalities such as quadricuspid aortic valve have been reported in this group of CAH patients. Average age of diagnosis is 20-30 years old (Miller and Merke. 2018. PubMed ID: 29734195).

In addition, rare heterozygous TNXB variants have been implicated in hereditary vesicoureteral reflux (VUR) in association with joint hypermobility (Gbadegesin et al. 2013. PubMed ID: 23620400; Elahi et al. 2015. PubMed ID: 26408188). VUR is the retrograde flow of urine from the bladder to the ureter and the kidney, representing the most common type of congenital anomaly of the kidney and the urinary tract (CAKUT).

Genetics

Defects in TNXB were originally found to cause EDS in an autosomal recessive manner (Burch et al. 1997. PubMed ID: 9288108; Schalkwijk et al. 2001. PubMed ID: 11642233). Later, heterozygous pathogenic variants in TNXB were implicated in hypermobility type EDS, suggesting an autosomal dominant inheritance (Zweers et al. 2003. PubMed ID: 12865992; Levy 2013. PubMed ID: 20301456).

Tenascin-X encoded by TNXB is an extracellular matrix protein acting as an important regulator of collagen deposition in vivo (Bristow et al. 2005. PubMed ID: 16278880; Mao et al. 2002. PubMed ID: 11925569). Defects in TNXB have been implicated in autosomal dominant or recessive type of Ehlers-Danlos syndrome as well as hereditary vesicoureteral reflux (VUR) (Schalkwijk et al. 2001. PubMed ID: 11642233; Zweers et al. 2003. PubMed ID: 12865992; Gbadegesin et al. 2013. PubMed ID: 23620400; Elahi et al. 2015. PubMed ID: 26408188).

TNXB is one of the constitutional genes of the RCCX module (RP-C4-CYP21-TNX) in the human leukocyte antigen histocompatibility complex on chromosome 6. The RCCX module represents a complicated genomic region characterized by frequent homologous recombination events due to existence of highly homologous pseudogenes in tandem (Lee. 2005. PubMed ID: 15639189; Chen et al. 2012. PubMed ID: 22156666). The pseudogene TNXA is a partially duplicated segment that corresponds to intron 31 to exon 44 of TNXB. A contiguous 30kb deletion disrupting both CYP21A2 and TNXB genes, resulting in a nonfunctional chimera TNXA/TNXB gene that contains the 120bp deletion crossing exon 35 and intron 35, is commonly found in patients (Schalkwijk et al. 2001. PubMed ID: 11642233; Koppens et al. 2002. PubMed ID: 12354783; Lindor et al. 2005. PubMed ID: 15793839; Merke et al. 2013. PubMed ID: 23284009). In addition, two types of chimera TNXA/TNXB genes (with different junction sites) that are not involving the 120 bp deletion have been reported in CAH patients with EDS phenotype (Morissette et al. 2015. PubMed ID: 26075496; Chen et al. 2016. PubMed ID: 27297501). Other documented genetic defects in TNXB are missense substitutions and truncating variants (small indels and splicing variants) (Human Gene Mutation Database). Pathogenic exon-level copy number changes have not been reported within the unique portion (exons 1 to 31) of TNXB.

De novo variants are rare in this gene. Both missense and loss-of-function variants can be pathogenic. TNXB has been cited as a nonessential gene for growth of human tissue culture cells (Online Gene Essentiality, ogee.medgenius.info)

Clinical Sensitivity - Sequencing with CNV PG-Select

In a group of 151 patients with the classic, hypermobility, or vascular types of the Ehlers-Danlos syndrome, five patients (3.3%) were found to have the common contiguous 30kb deletion allele (i.e. nonfunctional chimera TNXA/TNXB gene that contains the 120bp deletion crossing exon 35 and intron 35) or truncating variants (Schalkwijk et al. 2001. PubMed ID: 11642233).

In a cohort of 80 Dutch patients with hypermobility type Ehlers-Danlos syndrome, two patients (2.5%) were found to have a common contiguous 30kb deletion allele (nonfunctional chimera TNXA/TNXB gene that contains the 120bp deletion crossing exon 35 and intron 35) and a truncating 2bp deletion, respectively (Zweers et al. 2003. PubMed ID: 12865992).

In a study of 192 patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, the common contiguous 30kb deletion allele (nonfunctional chimera TNXA/TNXB gene that contains the 120bp deletion crossing exon 35 and intron 35) was found in a heterozygous state in 12 (6.25%) of these CAH patients (Merke et al. 2013. PubMed ID: 23284009). In addition, a heterozygous frameshift variant (c.6903insC) was also found in a patient (0.5%).

In a study of 246 unrelated CAH patients screened for TNXB defects, 14 CAH probands carried the TNXA/TNXB chimera involving the 120bp deletion (TNXA/TNXB CH-1) and 7 unrelated patients carried novel chimeras (TNXA/TNXB CH-2), leading to a CAH-X prevalence of 8.5% (Morissette et al. 2015. PubMed ID: 26075496).

In a study of 110 families with primary vesicoureteral reflux (PVUR), rare missense variants in TNXB were found in 5/55 (9%) of families with familial PVUR (FPVUR) and 2/55 (4%) of non-familial PVUR (NFPVUR) (Elahi et al. 2015. PubMed ID: 26408188).

Testing Strategy

This test is performed using Next-Gen sequencing with additional Sanger sequencing as necessary.

This test provides full coverage of all coding exons of the TNXB gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing.

Due to the homologous sequence at the region of intron 31 to exon 44, we utilize a long-range PCR strategy to specifically amplify and sequence these exons, which is able to overcome the limitation of current short-read NGS technology in dealing with this type of paralogous sequence (Mandelker et al. 2016. PubMed ID: 27228465).

Our test strategy is able to detect those TNXA/TNXB chimera alleles documented in the literature (Merke et al. 2013. PubMed ID: 23284009; Morissette et al. 2015. PubMed ID: 26075496; Chen et al. 2016. PubMed ID: 27297501).

Indications for Test

Candidates for this test are patients with Ehlers-Danlos syndrome due to complete tenascin-X deficiency, patients with hypermobility type Ehlers-Danlos syndrome or patients with hereditary vesicoureteral reflux (VUR) and joint hypermobility. This test can also be for patients affected by congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency with clinical evidence of hypermobility type Ehlers-Danlos syndrome. Testing is also indicated for family members of patients who have known TNXB pathogenic variants. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in TNXB.

Gene

Official Gene Symbol OMIM ID
TNXB 600985
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Citations

  • Bristow et al. 2005. PubMed ID: 16278880
  • Burch et al. 1997. PubMed ID: 9288108
  • Chen et al. 2009. PubMed ID: 19921645
  • Chen et al. 2012. PubMed ID: 22156666
  • Chen et al. 2016. PubMed ID: 27297501
  • Demirdas et al. 2017. PubMed ID: 27582382
  • Elahi et al. 2015. PubMed ID: 26408188
  • Gbadegesin et al. 2013. PubMed ID: 23620400
  • Human Gene Mutation Database (Bio-base).
  • Koppens et al. 2002. PubMed ID: 12354783
  • Lee. 2005. PubMed ID: 15639189
  • Levy. 2013. PubMed ID: 20301456
  • Lindor et al. 2005. PubMed ID: 15793839
  • Mandelker et al. 2016. PubMed ID: 27228465
  • Mao et al. 2002. PubMed ID: 11925569
  • Merke et al. 2013. PubMed ID: 23284009
  • Miller and Merke. 2018. PubMed ID: 29734195
  • Morissette et al. 2015. PubMed ID: 26075496
  • Schalkwijk et al. 2001. PubMed ID: 11642233
  • Zweers et al. 2003. PubMed ID: 12865992
  • Zweers et al. 2005. PubMed ID: 15733269

Ordering/Specimens

Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.


Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×

ORDER OPTIONS

An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)


1) Select Test Type


2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
×
Copy Text to Clipboard
×